Hydrocodone bitartrate q24h film-coated tablets

DRUG2 trials

Sponsors

Purdue Pharma LP

Conditions

Chronic Low Back PainChronic Nonmalignant and Nonneuropathic Pain

Phase 3

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

CompletedNCT01400139

Purdue Pharma LPChronic Nonmalignant and Nonneuropathic Pain

Start: 2011-07-31End: 2013-10-31Updated: 2020-03-10

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

CompletedNCT01452529

Purdue Pharma LPChronic Low Back Pain

Start: 2011-10-31End: 2013-10-31Updated: 2020-03-10

Related Papers

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.

2017-01-014 citations

Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.

2015-12-314 citations